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Background: Nonmotor symptoms are common among patients with Parkinson’s disease (PD) and some may
precede disease diagnosis.
Methods: We conducted a meta-analysis on the prevalence of selected nonmotor symptoms before and after PD
diagnosis, using random-effect models. We searched PubMed (1965 through October/November 2012) for the
following symptoms: hyposmia, constipation, rapid eye movement sleep behavior disorder, excessive daytime
sleepiness, depression, and anxiety. Eligible studies were publications in English with original data on one or more
of these symptoms.
Results: The search generated 2,373 non-duplicated publications and 332 met the inclusion criteria, mostly (n = 320)
on symptoms after PD diagnosis. For all symptoms, the prevalence was substantially higher in PD cases than in controls,
each affecting over a third of the patients. Hyposmia was the most prevalent (75.5% in cases vs. 19.1% in controls),
followed by constipation (50% vs. 17.7%), anxiety (39.9% vs. 19.1%), rapid eye movement sleep behavior disorder
(37.0% vs. 7.0%), depression (36.6% vs. 14.9%), and excessive daytime sleepiness (33.9% vs. 10.5%). We observed
substantial heterogeneities across studies and meta-regression analyses suggested that several factors might have
contributed to this. However, the prevalence estimates were fairly robust in several sensitivity analyses. Only 20
studies had data on any symptoms prior to PD diagnosis, but still the analyses revealed higher prevalence in future
PD cases than in controls.
Conclusion: These symptoms are common among PD patients both before and after diagnosis. Further studies are
needed to understand the natural history of nonmotor symptoms in PD and their etiological and clinical implications.
Keywords: Parkinson’s disease, Nonmotor symptoms, Meta-analysis, Prevalence, Natural historyParkinson disease (PD) is the second most prevalent
neurodegenerative disease and affects over one percent
of the elderly. In addition to motor dysfunction, PD pa-
tients also suffer from a variety of nonmotor symptoms
(NMS), ranging from hyposmia and depression early-on
to dementia and visual hallucination at later stages of
the disease. Many of these symptoms adversely affect the
quality of life of PD patients [1], and some may precede* Correspondence: chenh2@niehs.nih.gov
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unless otherwise stated.PD diagnosis by years [2]. These prodromal NMS include
hyposmia [3], constipation [4-6], depression [7,8], anxiety
[7,9], rapid eye movement sleep behavior disorder (RBD)
[10,11], and excessive daytime sleepiness (EDS) [12,13].
The presence of these NMS in prodromal PD is consistent
with the Braak hypothesis [14] which implies that they
may occur as the result of underlying Lewy pathogenesis
at olfactory bulb, enteric nerves, and lower brainstem, be-
fore invading substantia nigra. If this hypothesis were true,
investigation of early NMS may not only improve PD clin-
ical care, but also advance our knowledge of PD etiology
and natural history [15]. Fundamental to this research
is to understand the prevalence and incidence of eachhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of these symptoms in PD patients varies greatly across
published reports. For example, the reported proportion
of hyposmia among PD patients ranges from 27% [16] to
100% [17], and depression from 4% [18] to 80.5% [19]. We
therefore conducted meta-analyses to estimate the preva-
lence of these NMS before and after PD diagnosis.
Methods
Literature search and data abstraction
In October and November 2012, NIEHS librarians con-
ducted separate searches for publications on each of the
following NMS of PD: hyposmia, constipation, anxiety,
depression, EDS, and RBD. We selected these symptoms
because of clear evidence that they could develop prior to
PD diagnosis. The searches were primarily based on MeSH
terms for individual symptoms supplemented with key-
word searches in titles or abstracts specifically to identify
papers that had not yet been indexed by PubMed. We lim-
ited searches to studies that were relevant to PD by apply-
ing the MeSH Term/Major paper to “Parkinson Disease”
or searching for the keywords “Parkinson’s OR Parkinson
OR Parkinsons”. For MeSH terms, we used “olfaction
disorders” for hyposmia, “constipation” for constipation,
“depressive disorder” or “depression” for depression,
“anxiety” or “anxiety disorders” for anxiety, “disorders of
excessive somnolence” for EDS, and “REM sleep behavior
disorder” for RBD. For the keyword searches, we used
“olfact*”, “hyposmia”, “anosmia” or “smell” for hyposmia;
“constipat* or “bowel movement” for constipation;
“depress*” for depression, “anxiet*” or “anxious*” for
anxiety; “daytime sleepiness” for EDS; and “rapid eye
movement”, “rapid-eye-movement”, “REM”, or “RBD”
for RBD. In addition to these specific symptoms, we
also searched for general terms of pre-motor symptoms,
using “early diagnosis” as the MeSH term and “non-
motor” or “nonmotor”, or “premotor” or “pre-motor” or
“prodrom*” as keywords. The search was restricted to ori-
ginal publications on one or more of these NMS by limit-
ing searches to “Humans” and “English language” and by
excluding comments, case reports, editorials, reviews, or
letters. These searches generated a total of 2,298 entries.
These searches were further supplemented with 592 arti-
cles from a separate search conducted in June 2011. The
2011 search used a combination of MeSH terms and key-
words for PD and a broader range of individual NMS.
Combing these two searches, we identified a total of 2,890
references. After excluding 517 duplicates, 2,373 were left
for review.
Two authors independently screened the title and ab-
stract of each paper and full text if necessary to determine
study eligibility. Eligible studies are original publications
that either reported prevalence of one or more NMS or
provided original data from which prevalence could becalculated. Therefore, studies that only provided risk es-
timates such as relative risk without numbers of individ-
uals with the symptoms were not eligible. We excluded
studies for the following reasons: 1) duplicate popula-
tions (n = 22); 2) studies that did not have data on any
of the above-referenced NMS (n = 1,144); 3) publica-
tions without original data, such as reviews, comments,
editorials, or case-reports (n = 438); 4) non-English publi-
cations (n = 131); 5) non-human studies (n = 121); and 6)
studies that could not be generalized to late-onset spor-
adic PD (n = 185). The full texts of 332 eligible studies
were subsequently reviewed and relevant data were ab-
stracted. For papers that reported data on more than one
symptom, we abstracted data for each symptom separ-
ately. Similarly, for studies that reported data both after
and prior to PD diagnosis, relevant data were abstracted
separately. At each step, disagreements were resolved by
group discussion and re-reviews. The details of the litera-
ture search are shown in Figure 1 and the characteristics
of these studies are provided in Additional file 1: Table S1.
NMS assessments
Details of symptom assessment in individual studies are
provided in Additional file 1: Tables S2-S7. Assessment
methods varied across studies and are summarized in
Additional file 1: Table S8. Even for studies that used the
same method, often different cutoffs were used. For the
purpose of this meta-analysis, we refer NMS to symp-
toms rather than specific clinical diagnoses. Further, be-
cause we do not have original data of individual studies,
we adopted symptom definitions that were used in indi-
vidual studies.
Statistical analyses
For the purpose of this meta-analysis, prevalence was
defined as the proportion of individuals with a specific
symptom among PD patients or among participants
without PD (controls). As many clinical studies have a
small sample size, rather than using the standard sample
proportion to estimate prevalence, we used a Bayes esti-
mator as commonly advocated for such situations [20].
In particular, we used the Laplace estimator [21] by add-
ing one to the numerator (individuals with symptom)
and two to the denominator (total number of partici-
pants) to all studies in order to obtain a more reasonable
estimate in the meta-analyses. Such estimators of the
binomial proportion are often used when dealing rare
events to avoid zero estimates (with 0 standard error)
for events that occur with small probabilities. Pooled
prevalence estimates and standard errors were calculated
using the random-effects model to account for between-
study variations. Heterogeneity across studies was
assessed using Cochran Q and I2 statistics [22]. For
symptoms after diagnosis among PD cases, we further
Figure 1 Flow chart of literature review and data abstraction.
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of our estimates by removing studies with fewer than
50 PD cases, studies without controls, or studies that sim-
ply used self-reported symptoms in NMS assessment. We
assessed publication bias graphically using a funnel plot
and quantitatively using the Begg rank correlation test and
the Egger regression asymmetry test [23].
For symptoms after diagnosis, we further conducted
meta-regression analyses among cases to examine factors
that might have contributed to prevalence in individual
studies. In these analyses, we performed logit transform-
ation of the Laplace estimator since they are bounded be-
tween 0 and 1 and regression analysis requires unbounded
support [21]. Due to the small number of studies, we
did not conduct meta-regression analyses among con-
trols or pre-diagnostic cases and controls. For the same
reason, we did not evaluate publication bias for studies
prior to PD diagnosis. Data preparation was performed
using the SAS Software 9.3 (SAS Inc. Cary, NC) and
statistical analyses were performed using STATA, version
11.1 (StataCorp, College Station, TX).
Results
As shown in Figure 1, 320 studies reported data on
symptoms after PD diagnosis; the exact number varies
by symptoms from 39 for hyposmia to 170 for depres-
sion (Additional file 1: Table S1). Many studies provided
data only on PD cases, and fewer included controls. For
all symptoms, on average, approximately 60% of the
cases were men and the average age at symptom evalu-
ation was mid-60s, about seven years after diagnosis.Only 20 studies provided data on symptoms prior to PD
diagnosis. Of these, several publications used data from
large general purpose cohorts and therefore included
few cases but a very large number of controls. Further,
it is difficult to define the age or time of symptom as-
sessment as many studies assessed cumulative prevalence –
ever presence of symptoms prior to survey or disease
diagnosis. Details of individual studies are summarized
in Additional file 1: Tables S2-7.
Measurements of NMS
A variety of methods were used in the assessment of
NMS across studies and symptoms (Additional file 1:
Table S8). Generally speaking, self-report was commonly
used across symptoms. Structured questionnaires were
most frequently used for assessing anxiety, depression,
and EDS, while clinical examinations were used most
often for RBD. For hyposmia, most likely an objective
smell identification test was conducted.
Prevalence of symptoms after diagnoses
Each NMS affected at least a third of PD patients, 2.1
(anxiety) to 5.3 (RBD) times higher than the prevalence
in controls. Hyposmia was the most prevalent in cases
(75.5% vs. 19.1% in controls), followed by constipation
(50.0% vs. 17.7%), anxiety (39.9% vs. 19.1%), RBD (37.0%
vs. 7.0%), depression (36.6% vs. 14.9%), and EDS (33.9%
vs. 10.5%). Similar results were obtained from all three
sensitivity analyses (Table 1) (Figure 2).
There were however substantial heterogenities across
studies in these analyses (cases: I2 = 92.5% to 94.4%, all
Table 1 Sensitivity analyses of the prevalence of selected non-motor symptoms of PD after diagnosis
PD cases Controls
All data Sample size ≥50 Studies with controls Not self-reported
single symptom
All data Sample size ≥50 Not self-reported
single symptom
N % N % N % N % N % N % N %
Anxiety 54 39.9 ± 2.3 46 39.7 ± 2.5 5 33.9 ± 12.6 33 36.3 ± 2.4 5 19.1 ± 7.2 4 16.7 ± 7.7 2 17.3 ± 11.8
Constipation 50 50 ± 2.3 34 47.4 ± 2.5 14 44.8 ± 4.6 11 58.9 ± 5.8 14 17.7 ± 3.5 9 21 ± 4.2 3 16.7 ± 4.1
Depression 170 36.6 ± 1.4 136 35.7 ± 1.6 25 36.3 ± 3.7 145 35.6 ± 1.5 25 14.9 ± 1.8 20 15 ± 1.9 20 13.7 ± 1.8
EDS 74 33.9 ± 1.7 58 32.9 ± 1.9 22 32.8 ± 2.3 46 35.4 ± 1.8 22 10.5 ± 1.6 14 11.6 ± 2.1 17 9.2 ± 1.3
Hyposmia 39 75.5 ± 4.2 21 71 ± 5.9 17 76.5 ± 3.7 36 78.1 ± 2.7 17 19.1 ± 3.1 5 19.8 ± 5.5 16 20.1 ± 3.3
RBD 71 37 ± 1.8 51 36 ± 2 7 34.6 ± 8 53 39 ± 2.2 6 7 ± 2.4 3 7.4 ± 3.3 5 6.8 ± 3.4
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therefore conducted meta-regression analyses among
cases to evaluate potential sources of heterogenity
(Table 2). Age at examination was not a major contribu-
tor to study heterogenity except for EDS, which was
positively associated with age at examination. Disease
duration was positively related to the prevalence of con-
stipation and EDS across studies. Compared to studies
using self-reported symptoms, studies with clinical ex-
aminations or structured questionnaires showed lower
prevalence of anxiety. Studies using smell test showed
much higher prevalence of hyposmia than self-reports.
Compared to studies that were conducted in North
America, studies carried out in other areas of the world
showed higher prevalence of depression, and in Asia
higher prevalence of constipation.
Both visual inspections of the funnel plots and statis-
tical tests (data not shown) suggest publication bias for
studies that examined the prevalence of anxiety, contipa-
tion, depression, and EDS among cases after PD diagnosis,
and for depression and hyposmia among controls (EggerFigure 2 Meta-analysis of the prevalence of selected non-motor symptest: P < 0.05). The positive Egger’s bias coefficients for
these studies suggest that more extreme estimates from
smaller studies were more likely to be published than less
extreme estimates.Prevalence of symptoms prior to diagnoses
Few studies have data on NMS prior to PD diagnosis
and most assessed symptoms via self-report. Despite
these limitations, it is clear that the prevalence of these
symptoms prior to PD diagnosis was higher among future
PD cases than controls. The differences were, however,
smaller than post-diagnosis data. Once again, hyposmia
was the most prevalent, 35.5% in future cases versus
17.4% in controls, followed by depression (23.0% vs.
14.9%), constipation (20.0% vs. 9.3%), anxiety (18.8% vs.
10.5%), and RBD (17.9% for cases). Because only one
study assessed EDS prior to PD diagnosis or RBD
among controls, no summary estimates were calculated.
Like the post-diagnosis analyses, significant study heteroge-
neities were observed across symptoms (cases: I2 = 79.1%toms after PD diagnosis.
Table 2 Patient characteristics and non-motor symptoms of PD meta-regression analysis among casesa
Anxiety Constipation Depression EDS Hyposmia RBD
(N = 48) (N = 39) (N = 132) (N = 63) (N = 31) (N = 58)
Age at examination −0.0229428 0.0005514 −0.0123411 0.0664692b 0.0188255 0.0099428
Percent men −2.136381 −0.2987655 0.3672128 1.512528 −1.614856 −0.4417779
Disease duration −0.0117009 0.1112542b 0.0342322 0.0841153b −0.0535196 −0.0164648
Symptom assessment
(ref = Self-report symptom)c
Clinical exam/diagnosis −0.7969928b N/A −0.2571586 N/A N/A 0.4188744
Structured questionnaire −0.6081471b 0.4599401 0.0039112 0.0728903 N/A 0.5019682
Smell test N/A N/A N/A N/A 1.580798b N/A
Continent (ref =North America) Europe 0.2150189 0.1268662 0.4494578b −0.152538 0.1744257 −0.0748215
Asia −0.7000721 1.174114b 0.9805807b −0.292603 −0.5923392 −0.3263885
Other 0.051124 0.6902194 0.6824674b 0.2518004 −0.018769 −0.1487844
aCorrelation coefficients were presented.
bP < 0.05.
cMethods with fewer than 5 studies were not included in the analyses.
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(Figure 3).
Discussion
It is well-known that NMS are common among PD pa-
tients; however, the exact prevalence and incidence are
yet to be defined. To the best of our knowledge, this is
the first comprehensive meta-analysis on the prevalence
of multiple important NMS before and after PD diagno-
sis. A previous meta-analysis examined NMS and other
factors in relation to PD risk [24]; however, it provided
no data on symptom prevalence. The goal of our analysis
was to survey available data and to provide preliminary
prevalence estimates for future research on premotor
symptoms of PD. As there are limited number of studies
that were specifically designed to assess the prevalenceFigure 3 Meta-analysis of the prevalence of selected non-motor sympof these symptoms, particularly prior to diagnosis, and
among available studies, there are substantial heteroge-
neities in study population and symptom assessment, we
have decided to be inclusive rather than exclusive in the
selection of eligible studies.
Understanding the prevalence of NMS among PD
patients is important in multiple ways. NMS adversely
affect the quality of life of PD patients. Depression and
sleep disturbances are often cited as the most important
determinants of the health-related quality of life among
PD patients [1,25]. A good understanding of the preva-
lence of these symptoms allows for more comprehensive
assessments of disease burden and better clinical man-
agements. Some NMS, like the ones we analyzed, may
precede PD diagnosis by years. Research on these symp-
toms may help us better define at-risk populations intoms prior to PD diagnosis.
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example, several recent studies were carried out to
examine whether hyposmia alone or with other NMS and
neuro-biomarkers might help identify PD earlier than clin-
ical diagnosis [27-29]. Equally important, this may also
provide an unprecedented opportunity to investigate the
origin and early etiology of PD as exemplified by the dual-
hit hypothesis [30,31]. These prodromal symptoms may
serve as intermediate phenotypes to investigate risk fac-
tors that contribute to early PD development and to later
conversion from intermediate phenotypes to clinical PD
[15]. This research has been pioneered by experimental
studies [31] and clinical investigations among RBD
patients [32], and future population-based studies will
be needed.
Our analyses systematically evaluated the prevalence
of selected NMS before and after PD diagnosis. We
clearly demonstrated that each of these symptoms af-
fected at least a third of PD patients. Of these, hyposmia
was the most prevalent, affecting 76% of PD patients
after diagnosis and 36% prior to diagnosis. Although not
directly comparable, all NMS in patients were about
twice as prevalent after diagnosis as prior to diagnosis.
This is consistent with the Braak hypothesis that the
Lewy pathology is cumulative in PD [14] and also with
the progressive nature of PD development. The preva-
lence of these symptoms was clearly higher in cases than
in controls. After diagnosis, the largest difference was
found for RBD, followed by hyposmia, EDS, and consti-
pation, each about 3–5 times more prevalent among
cases than among controls. Prior to diagnosis, the differ-
ence is however smaller, generally less than 2-fold. This,
together with the relative high prevalence of symptoms
among controls, supports the notion that most of these
NMS are not specific; therefore future studies should
focus on understanding patterns of multiple NMS and
how they are related to future PD development [15,33].
Notably, population data on prodromal PD are fairly
limited and little data exist on the prevalence of EDS
and RBD prior to PD diagnosis. Previous clinical-based
studies suggest that RBD is the most specific prodromal
symptom for PD [34], and this issue should be further
evaluated in population-based studies.
It is not surprising that there are substantial heterogene-
ities across studies given the large variability in symptom
definition, assessment methods, and patient characteris-
tics. Many of the studies assessed symptoms via self-
reports, which may be very useful to screen large popula-
tions cost-effectively but are not ideal for estimating
prevalence. We found in the meta-regression analysis that
self-reports might have underestimated the prevalence of
hyposmia, but overestimated that for anxiety. This sug-
gests that hyposmia are under-recognized by the elderly
and objective means are needed to screen for smell deficit,such as the Sniffin’ Stick test [35] or the Brief Smell Iden-
tification Test [36]. Interestingly, with a few exceptions,
we did not identify age and disease duration as major
contributors to study heterogenity. This may relate to the
fact that we analyzed aggregated data across studies, and
this issue could be better investigated in large studies with
indivdiual data.
In non-PD literature, prevalence data for the general
population are widely available on depression, anxiety, and
to a lesser extent, on constipation and hyposmia. Compar-
ing our data directly with those is difficult, in part due
to differences in study design, population characteris-
tics, symptom assessment, and definitions of symptom
prevalence. With these caveats, our data for controls are
largely consistent with reports from several recent
meta-analyses on constipation [37], depression [38], and
anxiety [38] in general elderly populations. To the best
of our knowledge, no other meta-analysis has been con-
ducted on hyposmia. Our analyses showed that approxi-
mately 19% of the elderly population free of PD had
hyposmia, which was also comparable to studies in the
general older population [39]. While little data have
been published on EDS and RBD outside the PD litera-
ture, our meta-analysis suggests that these symptoms
may affect 7-10% of the elderly without PD.
Our analyses have several limitations. We limited our
search to PubMed and publications in English and there-
fore might have missed a small number of relevant publi-
cations. Most studies were not originally designed to
evaluate the prevalence of NMS, and there were substan-
tial heterogeneities in the source population, study design,
sample size, and symptom assessment. Nevertheless, we
conducted several sensitivity analyses for symptoms after
disease diagnosis and obtained similar results. Further,
few studies have data prior to PD diagnosis, and there-
fore the corresponding estimates may not be as stable as
those for post-diagnostic prevalence. Moreover, it is
important to understand the temporal relationship of
NMS to PD, particularly in the prodromal stage. How-
ever, nearly all studies had only cross-sectional mea-
surements, and prospective investigations with repeated
assessments are largely lacking. Finally, few previous
studies examined the occurrence of multiple symptoms,
which allows for a more comprehensive assessment of
NMS burden among PD patients. Such assessment in
the prodromal stage of PD may further help to better
identify populations at risk despite that individual NMS
are mostly not specific to PD [15].
Despite these limitations, our meta-analysis provided
summary estimates of NMS among PD before and after
diagnosis. Further prospective research is needed to exam-
ine the presence of multiple symptoms and their temporal
relationships to PD to better understand the etiology and
natural history of NMS and PD.
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